biontech (bntx) up on initial data from lung cancer antibody. biontech&rsquo.sbntx shares rose almost 4% on jun 2. this occurred soon after interim data from an ongoing phase i/ii study on its

why shares of biontech rose friday. what happened shares of biontech (nasdaq: bntx) were up as by much as 5.3% on friday before closing the session up 3.85% after the biotech company announced positive news regarding a clinical trial for its no

biontech reports promising data on bnt316 phase 3 trial slated for q3.

biontechs oncoc4 partnership off to good start with mid-stage trial results. biontech said on friday that a new cancer immunotherapy candidate that it is working on with United States partner oncoc4 inc was shown to shrink tumours in close to 30

amended european deal for biontech-pfizers covid-19 vaccines allows reduced purchases. the european commission (ec) hadwith) and

curevac files expanded patent lawsuit against pfizer/biontech over mrna technology. curevac nv said on friday it had filed an expanded patent infringement claim against pfizer inc and biontech over the use of mrna technology and that a United St

earnings scheduled for may 8 2023. &. hni (nyse:) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million. &. axsome therapeutics (nasdaq:) is projected to report quarterly loss at $1.04 per share on revenue of $26.07 million.

biontech revenue falls. why the stock is climbing anyway..

biontech earnings drops on lower covid vaccine sales. biontech pfizers partner on covid-19 vaccines said first-quarter net income plunged on lower demand for the shots as the german biotech firm broadens its attention on cancer and other infecti

cash-rich biontech broadens scope as covid shot sales slide. germanys biontech pfizers partner on covid-19 vaccines said on monday its first-quarter net income plunged on lower demand for the shots as it widens its work on cancer and other disea

biontech q1 net profit declines. reiterates 2023 covid-19 vaccine revenue guidance. (rttnews) - biontech se (bntx) said its financial performance has been fully in line with the companys expectations for the first quarter of 2023. commercial rev

biontech beats q1 top and bottom line estimates. reaffirms fy23 outlook.

european unions amended covid-19 vaccine deal with pfizer-biontech: near-monopoly status potential threat to rivals. the european union bloc is reportedly negotiating an amended deal with) and) for around 70 million covid-19 vaccine doses despite the euro

wuxi biologics and wuxi xdc congratulate dualitybio on entering global licensing and collaboration agreements with biontech to accelerate development of differentiated antibody-drug conjugate therapeutics.

biontech stock price target cut to $128 from $142 at j.p. morgan. this is a real-time headline. these are breaking news delivered the minute it happens delivered ticker-tape style. visit www.marketwatch.com or the e page for more information about this br